This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Roche Holding AG

Drug Names(s): CP-358774, erlotinib, OSI-774, R1415, RG1415, Ro50-8231, NSC 718781

Description: Tarceva is a small molecule that influences the biological activity of the epidermal growth factor receptor (EGFR). Other drugs that impact this target are Iressa, Erbitux, and ABX-EGF. AstraZeneca's Iressa, also a small molecule, is the first approved EGFR inhibitor. ImClone and Bristol Myers Squibb's Erbitux as well as Abgenix and Amgen's ABX-EGF are monoclonal antibodies.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

Tarceva was originally developed by Pfizer.

In June 2000, Pfizer merged with Warner-Lambert. The resulting company retained the Pfizer name, but in order to meet Federal Trade Commission requirements for the merger, Pfizer granted a worldwide, royalty-free license for erlotinib to its developmental partner, OSI Pharmaceuticals.

Genentech (Roche) and OSI (Astellas)
Under the co-promotion arrangement, all U.S. sales of Tarceva and associated costs and expenses, except for a portion of OSI sales related costs, are recognized by Genentech. OSI records 50% share of the co-promotion pretax profit on a quarterly basis. Pretax co-promotion profit (loss) under the co-promotion arrangement is derived by calculating U.S. net sales of Tarceva to third-party customers and deducting costs of sales, distribution, selling and marketing expenses, and certain joint development expenses incurred by Genentech and OSI.

In...See full deal structure in Biomedtracker

Partners: Astellas Pharma, Inc. Chugai Pharmaceutical Co., Ltd.

Tarceva News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug